MOR vs. VTRS, ASND, PCVX, QGEN, ROIV, SRPT, RVMD, BBIO, LNTH, and TGTX
Should you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Viatris (VTRS), Ascendis Pharma A/S (ASND), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), Sarepta Therapeutics (SRPT), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Lantheus (LNTH), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.
MorphoSys vs.
MorphoSys (NASDAQ:MOR) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, community ranking, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.
In the previous week, Viatris had 15 more articles in the media than MorphoSys. MarketBeat recorded 16 mentions for Viatris and 1 mentions for MorphoSys. MorphoSys' average media sentiment score of 1.05 beat Viatris' score of 0.02 indicating that MorphoSys is being referred to more favorably in the media.
MorphoSys received 2 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 38.46% of users gave MorphoSys an outperform vote while only 34.85% of users gave Viatris an outperform vote.
18.4% of MorphoSys shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 0.1% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Viatris has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.
Viatris has higher revenue and earnings than MorphoSys. Viatris is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
Viatris has a net margin of -5.87% compared to MorphoSys' net margin of -226.79%. Viatris' return on equity of 16.46% beat MorphoSys' return on equity.
Viatris has a consensus target price of $10.50, indicating a potential upside of 18.78%. Given Viatris' stronger consensus rating and higher possible upside, analysts clearly believe Viatris is more favorable than MorphoSys.
Summary
Viatris beats MorphoSys on 12 of the 18 factors compared between the two stocks.
Get MorphoSys News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MorphoSys Competitors List
Related Companies and Tools
This page (NASDAQ:MOR) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy MOR Stock Free MOR Stock Alerts